Reported Earlier, Ascentage Pharma Wins China Breakthrough Therapy Designation For Bcl-2 Inhibitor Lisaftoclax Plus Acalabrutinib In Treatment-Naïve CLL/SLL

Loading news article.

Reported Earlier, Ascentage Pharma Wins China Breakthrough Therapy Designation For Bcl-2 Inhibitor Lisaftoclax Plus Acalabrutinib In Treatment-Naïve CLL/SLL | WAPE

Reported Earlier, Ascentage Pharma Wins China Breakthrough Therapy Designation For Bcl-2 Inhibitor Lisaftoclax Plus Acalabrutinib In Treatment-Naïve CLL/SLL

Article summary

Related companies

Comments —